Literature DB >> 12349884

Is it really possible to build a bridge between cost-benefit analysis and cost-effectiveness analysis?

Paul Dolan1, Richard Edlin.   

Abstract

Cost-benefit analysis (CBA) is a recognised as the economic evaluation technique that accords most with the underlying principles of standard welfare economic theory. However, due to problems associated with the technique, economists evaluating resources allocation decisions in health care have most often used cost-effective analysis (CEA), in which health benefits are expressed in non-monetary units. As a result, attempts have been made to build a welfare economic bridge between cost-benefit analysis (CBA) and cost-effectiveness analysis (CEA). In this paper, we develops these attempts and finds that, while assumptions can be made to facilitate a constant willingness-to-pay per unit of health outcome, these restrictions are highly unrealistic. We develop an impossibility theorem that shows it is not possible to link CBA and CEA if: (i) the axioms of expected utility theory hold; (ii) the quality-adjusted life-year (QALY) model is valid in a welfare economic sense; and (iii) illness affects the ability to enjoy consumption. We conclude that, within a welfare economic framework, it would be unwise to rely on a link between CBA and CEA in economic evaluations.

Mesh:

Year:  2002        PMID: 12349884     DOI: 10.1016/s0167-6296(02)00011-5

Source DB:  PubMed          Journal:  J Health Econ        ISSN: 0167-6296            Impact factor:   3.883


  10 in total

1.  Exploring a new method for deriving the monetary value of a QALY.

Authors:  Carl Tilling; Marieke Krol; Arthur E Attema; Aki Tsuchiya; John Brazier; Job van Exel; Werner Brouwer
Journal:  Eur J Health Econ       Date:  2015-08-20

Review 2.  Willingness to pay for a QALY: theoretical and methodological issues.

Authors:  Dorte Gyrd-Hansen
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 3.  Utility measurement in healthcare: the things I never got to.

Authors:  George W Torrance
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

4.  A multi-criteria decision analysis perspective on the health economic evaluation of medical interventions.

Authors:  Douwe Postmus; Tommi Tervonen; Gert van Valkenhoef; Hans L Hillege; Erik Buskens
Journal:  Eur J Health Econ       Date:  2013-07-11

5.  Balancing equity and efficiency in the Dutch basic benefits package using the principle of proportional shortfall.

Authors:  E J van de Wetering; E A Stolk; N J A van Exel; W B F Brouwer
Journal:  Eur J Health Econ       Date:  2011-08-26

Review 6.  A systematic review of studies eliciting willingness-to-pay per quality-adjusted life year: does it justify CE threshold?

Authors:  Khachapon Nimdet; Nathorn Chaiyakunapruk; Kittaya Vichansavakul; Surachat Ngorsuraches
Journal:  PLoS One       Date:  2015-04-09       Impact factor: 3.240

7.  Burden of micronutrient deficiencies by socio-economic strata in children aged 6 months to 5 years in the Philippines.

Authors:  Simon Wieser; Rafael Plessow; Klaus Eichler; Olivia Malek; Mario V Capanzana; Imelda Agdeppa; Urs Bruegger
Journal:  BMC Public Health       Date:  2013-12-11       Impact factor: 3.295

8.  Assessment of the societal and individual preferences for fertility treatment in Australia: study protocol for stated preference discrete choice experiments.

Authors:  Willings Botha; Natasha Donnolley; Marian Shanahan; Georgina M Chambers
Journal:  BMJ Open       Date:  2018-02-14       Impact factor: 2.692

9.  New findings from the time trade-off for income approach to elicit willingness to pay for a quality adjusted life year.

Authors:  Arthur E Attema; Marieke Krol; Job van Exel; Werner B F Brouwer
Journal:  Eur J Health Econ       Date:  2017-03-08

Review 10.  Welfarism versus extra-welfarism: can the choice of economic evaluation approach impact on the adoption decisions recommended by economic evaluation studies?

Authors:  James Buchanan; Sarah Wordsworth
Journal:  Pharmacoeconomics       Date:  2015-06       Impact factor: 4.981

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.